THE EXPRESSION LEVEL OF HLS5 IS CORRELATED WITH THE CLINICAL OUTCOMES OF ACUTE LYMPHOID LEUKEMIA (ALL) PATIENTS
(Abstract release date: 05/19/16)
EHA Library. HUANG J. 06/09/16; 134507; PB1607
Prof. Dr. JIAN HUANG
Contributions
Contributions
Abstract
Abstract: PB1607
Type: Publication Only
Background
HLS5 belongs to the RBCC (Ring-finger, B-box, coiled-coil) family, a family of tumor suppressive genes including Pm, Tif1-α,Herf and Rfp, it has been reported to regulate erythroid differentiation, to be activated during the conversion of J2E erythroleukemic cells to monocytoid cells, and assumed to be a tumor supressor. However, the role of HLS5 in acute lymphoblastic leukemia has never been explored.
Aims
To identify the expression of HLS5 and the relationship to the clinical outcom to ALL.
Methods
Bone marrow of 63 de novo ALL patients were collected, the mononucleated cells separated, RNA extracted and the HLS5 expression level detected using real-time quantitative PCR. SPSS 16.0 used for data analysis.
Results
The high HLS5 expression level (the higher 25% of all the patients) is correlated with longer overall survival and event free survival (both p˂0.05), but the correlations between HLS5 expression level and blast count, WBC, Hb level, platelet count, IK6 status and Ph chromosome status are not significant.
Conclusion
The expression level of HLS5 in de novo ALL patients may associate with the clinical outcome, but the exact mechanism needs further investigation.
Session topic: E-poster
Keyword(s): ALL
Type: Publication Only
Background
HLS5 belongs to the RBCC (Ring-finger, B-box, coiled-coil) family, a family of tumor suppressive genes including Pm, Tif1-α,Herf and Rfp, it has been reported to regulate erythroid differentiation, to be activated during the conversion of J2E erythroleukemic cells to monocytoid cells, and assumed to be a tumor supressor. However, the role of HLS5 in acute lymphoblastic leukemia has never been explored.
Aims
To identify the expression of HLS5 and the relationship to the clinical outcom to ALL.
Methods
Bone marrow of 63 de novo ALL patients were collected, the mononucleated cells separated, RNA extracted and the HLS5 expression level detected using real-time quantitative PCR. SPSS 16.0 used for data analysis.
Results
The high HLS5 expression level (the higher 25% of all the patients) is correlated with longer overall survival and event free survival (both p˂0.05), but the correlations between HLS5 expression level and blast count, WBC, Hb level, platelet count, IK6 status and Ph chromosome status are not significant.
Conclusion
The expression level of HLS5 in de novo ALL patients may associate with the clinical outcome, but the exact mechanism needs further investigation.
Session topic: E-poster
Keyword(s): ALL
Abstract: PB1607
Type: Publication Only
Background
HLS5 belongs to the RBCC (Ring-finger, B-box, coiled-coil) family, a family of tumor suppressive genes including Pm, Tif1-α,Herf and Rfp, it has been reported to regulate erythroid differentiation, to be activated during the conversion of J2E erythroleukemic cells to monocytoid cells, and assumed to be a tumor supressor. However, the role of HLS5 in acute lymphoblastic leukemia has never been explored.
Aims
To identify the expression of HLS5 and the relationship to the clinical outcom to ALL.
Methods
Bone marrow of 63 de novo ALL patients were collected, the mononucleated cells separated, RNA extracted and the HLS5 expression level detected using real-time quantitative PCR. SPSS 16.0 used for data analysis.
Results
The high HLS5 expression level (the higher 25% of all the patients) is correlated with longer overall survival and event free survival (both p˂0.05), but the correlations between HLS5 expression level and blast count, WBC, Hb level, platelet count, IK6 status and Ph chromosome status are not significant.
Conclusion
The expression level of HLS5 in de novo ALL patients may associate with the clinical outcome, but the exact mechanism needs further investigation.
Session topic: E-poster
Keyword(s): ALL
Type: Publication Only
Background
HLS5 belongs to the RBCC (Ring-finger, B-box, coiled-coil) family, a family of tumor suppressive genes including Pm, Tif1-α,Herf and Rfp, it has been reported to regulate erythroid differentiation, to be activated during the conversion of J2E erythroleukemic cells to monocytoid cells, and assumed to be a tumor supressor. However, the role of HLS5 in acute lymphoblastic leukemia has never been explored.
Aims
To identify the expression of HLS5 and the relationship to the clinical outcom to ALL.
Methods
Bone marrow of 63 de novo ALL patients were collected, the mononucleated cells separated, RNA extracted and the HLS5 expression level detected using real-time quantitative PCR. SPSS 16.0 used for data analysis.
Results
The high HLS5 expression level (the higher 25% of all the patients) is correlated with longer overall survival and event free survival (both p˂0.05), but the correlations between HLS5 expression level and blast count, WBC, Hb level, platelet count, IK6 status and Ph chromosome status are not significant.
Conclusion
The expression level of HLS5 in de novo ALL patients may associate with the clinical outcome, but the exact mechanism needs further investigation.
Session topic: E-poster
Keyword(s): ALL
{{ help_message }}
{{filter}}